Lumiaâ„¢, a company developing a continuous blood flow tracking wearable, has announced it has successfully raised $5,100,000 in investment capital. This funding round marks a significant step for the company as it advances its mission to provide innovative health solutions for chronic conditions. The capital infusion will enable Lumiaâ„¢ to further its development and market reach.
The company is building the world’s first and only continuous blood flow tracking wearable, designed to assist the more than 100 million Americans living with chronic neurological and cardiovascular conditions. Lumia™ is initially focusing on serving as a wellness tracker for individuals who experience symptoms such as dizziness, brain fog, fatigue, and fainting when standing. These symptoms are frequently associated with conditions including Long COVID, Postural Orthostatic Tachycardia Syndrome (POTS), Orthostatic Hypotension, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and general orthostatic intolerance, highlighting a significant need for its technology.
Lumiaâ„¢ plans to utilize the newly secured funds to accelerate its growth initiatives, including ongoing product development, scaling its operational capabilities, and expanding its team. This investment underscores confidence in Lumiaâ„¢'s innovative approach to addressing critical health challenges and its potential to improve daily life for millions. The company is committed to advancing its technology and making its unique wearable accessible to more individuals, supporting its long-term vision of providing continuous physiological insights.
.png&w=3840&q=75)
